Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Revenio, Audiocast, Q2'26

By Inderes9/8/2026, 12:00 PM
Revenio Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jukka Kainulainen
00:01 - 01:15

Good afternoon, and welcome to the Revenio Q2 earnings call. My name is Jouni Toijala, and I am extremely happy to have Jukka Kainulainen joining in the call with me today. Jukka has started as our new CFO about a week ago, right? Yeah. Right. Jukka. It has been almost two weeks. So so yeah. Would you like to introduce Jukka first yourself and then we get to the agenda. Yeah. Thank you, Jouni. And of course, I am very excited to be here. It is a very exciting moment. This is an exciting moment for Revenio after the strategic acquisition and starting a totally new journey as a new combined company. It is great to be here, and previously I have spent the last ten years in global technology growth companies, focusing always on growth, profitability, capital allocation, and acquisitions. A little bit earlier in my career, I also gained experience related to integration topics. So great to be here and thanks a lot, Jouni.

Jouni Toijala
01:16 - 12:39

Hey. Thank you. Let's jump to the agenda. We are going to conduct a somewhat different earnings call today. We will start with the Visionix integration status. Then we are also going to go through where we stand regarding the synergies. We discussed during the transaction closing and announcement the 20 million EBITDA uplift target. We are going to recap that. Then, of course, we are going through the highlights of the second quarter and the first half of 2026. Jukka is going to do a deep dive into the finance part. And then, of course, we have a guidance at the very end, before jumping to the integration and synergy. As you said, it is nice to join the company because we are having quite a historic moment now ongoing. I would compare this to the CenterVue acquisition at the time in terms of significance; of course, the size is bigger now, but I still refer to the old Revenio, if I may use the term. That is, of course, considerably sizable compared to 2019. This is the first quarter when we now have one month of numbers in from the Visionix side. Based on the first 100 days, if I may use the 100-day term here. Everything is progressing well and according to the plan. The strategic logic why we closed the transaction is still as strong as it was at the time of the signing and closing, which I found extremely encouraging and good. From the integration perspective, integration is progressing really well. We have a couple of scenarios here. I would summarize that we are now leaning towards the best-case scenario in terms of the speed of realizing synergies and integrating the organization. If we look at a couple of key areas here. First, from the overall integration perspective. We have now nailed down, as of the end of May, the leadership team organization, the board structure, and the overall governance. And then during the summer time, we moved further down into the organization in order to clarify the organization and operative model. That is going really well in terms of the culture. We ran an extensive culture audit during the summer, and the cultures are actually matching together extremely well. And this is, at least for me, a more positive thing than I was expecting, as we have been putting a lot of effort into the commercial activation and to securing business continuity. The US sales team is performing well. We have actually combined the US organization, including sales, and the new team has been running operationally from the beginning of August. And what we have done in the USA. We have also finalized all product training related to the different products for the team. And then also now, bit by bit, we are moving to cross-sales targets. And really moving to the execution in the past 4 to 5 weeks on the international sales side, which Marc Abitbol is running. Jouni is running the US sales organization. From the international side, we have clear plans now on how to start moving forward with the different countries, whether they are direct or through distribution. That has moved to execution in the last two weeks. And I would say that the overall progress has been extremely positive. Coming back to the 20 million EBITA uplift, we have already secured, a bit ahead of time, the 5 million run rate savings regarding the 20 million EBITA uplift. So we are on track. We also have plans regarding the next steps for our operating model and matters related to procurement, etc. In order to be able to get the remaining part of the 15 million EBITA uplift in the coming quarters. To summarize the integration status in one sentence. It is going well. And according to the plan, let's turn to the numbers. So of course, the top line is up 39.3 million, which is roughly 50% higher. What we saw on the profitability side is, of course, that we have been coming down due to a couple of things affecting profitability. The first factor is acquisition-related. One-off costs, which during Q2 were roughly 3.4 million. You are going to cover that in a bit more detail, but I think that we should also pay attention to the gross margin, which was exceptionally high in the previous year. Q2. It was roughly 72.6%. And if we go back to Q2 last year. We actually did not have a tariff impact almost at all at the time. So we were stacking a lot of products into the warehouse. We did not pay any tariffs on the imaging products. We did not pay any tariffs regarding the mirrors. We started to pay some tariffs towards the end of Q2 last year. Regarding the probes. And if we look then from the gross margin perspective, Q2, Q3, Q4, and Q1 this year. I think we are able to say that we had the gross margin beyond 70%. That is partly explaining why the gross margin is down. And of course, we have a Visionix dilution. But you are going to cover this in more detail. Then regarding the whole first half. Regarding the first half, net sales were 66.6 up from 52.6, and the operating profit was 4.8. And then we had, in addition to the 3.4 million. We had roughly the same amount of acquisition-related one-off costs during Q1 as well. So the whole acquisition-related expenses were a ballpark of 6.9 million. Then regarding cash flow. Jukka is going to cover this one, but the cash flow was negative. And let's also come back to Jukka's presentation. So we had a really strong cash flow, exceptionally strong in Q4 last year, at roughly 15 million. So part of the costs were actually occurring during the Q1. Then after that. Q2. So a couple of highlights from the other parts of the business. We have now been working closely with iHealthScreen regarding the drsplus and the FDA clearance. We have now managed to get the first FDA-cleared AI solution for the USA. That is extremely good news. We are now working closely with iHealthScreen in order to approach customers and start pitching the product. We look for this to boost the DRSplus sales in the coming quarters and years in the USA. And then another thing where we have been active and working for a long time in the USA and, of course, in other parts of the world. And this is really linking to the macro trends that we are seeing, i.e. The number of patients is increasing. The resources on the eye health professional side are limited, and we are not able to treat and diagnose all the patients. In our constant communications, we have been emphasizing the ease of use and automation regarding our devices. This is a prime example of that. So we closed a strategic partnership in the USA with a company called EyeCheq, which is providing the kiosk where we have been integrating the DRSplus for autonomous use and for the screening purposes. And then this kiosk is connected to the back-end platform, and the patient is able to come to the kiosk and do the holistic screening of the eye. This is an extremely positive development for us in terms of the long run and clearly shows where the market is going in the future. But with these words, let's move to the more detailed finances. So yeah, over to you, please.

Jukka Kainulainen
12:39 - 19:48

Thank you Yoni. And let's start with the key figures for the quarter, and maybe starting first with Visionix. It is good to remember that Visionix has been consolidated to the group numbers starting from the beginning of June. So one month of Visionix is included in our June numbers, and looking at the top-line development, net sales increased 48.1%, with currency-adjusted growth at 50.7%. And when looking at the underlying business, our organic growth was more or less flat for the quarter, and the gross margin went down to 65%. Rounding it up, comparing high comparables of 73% for the quarter to last year, I am going to go a little bit more in detail in the following slide. And then when looking at the adjusted EBITA for the quarter, it was €5.8 million. So 14.6% of net sales, and that included €3.4 million in acquisition-related non-recurring expenses. So overall, this was quite a good start for the new combined company and it is a good build. We can build the future based on this one. Then, let's look at net sales development in a little bit more detail. The step up in revenue, as you see in the second quarter, came from the Visionix impact. As I commented on the previous slide. So, organic growth was more or less flat. And when looking at the net sales development in different geographies, it was negatively affected by the market environments in the Middle East and Asia regions. And then, at the same time, we see some positive development in our Europe region overall. Then, let us move to profitability. As I commented, adjusted operating profit was €5.8 million during the quarter, 14.6% of the net sales, and the gross margin declined to 64.7%, compared to 72.6% during the second quarter of 2025. It is good to remember that the comparable gross margin was really high, like Jouni commented when looking at all of last year. Gross margin. It was 71%. So quarter two 2025 was a very high comparable. But then at the same time, when Visionix was consolidated into the group numbers, that had an actual two percentage point dilutive impact due to the lower margin profile of the Visionix business. And then when looking at the underlying business, the gross margin in that business went down by five percentage points. That was driven by, for example, the tariffs, which we did not have in last year's second-quarter numbers. And there was some increase in the unit costs, for example, on the electronic component side. And then also overall, there was some increase in our fixed costs during the quarter. Two 2026. Then moving on to the cash flow, cash flow from operations was negative by €2.4 million during the quarter. And it's good to remember that it included around €3 million of payments. Regarding the acquisition and the related project we are running. And at the same time, our net working capital increased at the end of the quarter, especially relating to accounts receivable. And this is not a normalized run rate. Of course, it is more like a temporary situation regarding the acquisition. When looking at both companies' cash flow generation, Revenio has always been very strong cash flow-wise in H2, especially in quarter four, and the Visionix business has a very similar cash flow profile. So a major part of the cash flow is generated in H2 comparing to H1 for the calendar year, then moving on to the balance sheet and balance sheet metrics, which are of course quite a lot reflected by acquisition financing, and net debt is now at €138 million. So it is temporarily up, including the €130 million term loan that we closed in quarter two, also the €80 million bridge-to-equity facility and the €17 million vendor loan also relating to the acquisition. And then on top of that, we have revolving credit facilities in use of around €20 million at the moment. And when looking at these balance sheet metrics, the equity ratio at the moment is 31.2% and net debt to adjusted EBITDA is temporarily up at 5.3. And then it is good to remember what we have communicated also earlier. So we are planning this post-completion rights issue of €80 million that will happen during the H2 2026. The purpose of the rights issue is to pay out this bridge-to-equity facility. And through that, of course, strengthen our balance sheet and improve our leverage metrics overall. Then briefly, our shareholders base. So here is the latest cap table. And as you know, Revenio is quite global when looking from the shareholders' point of view. More than 50% of the ownership is outside Finland. And of course, regarding recent changes you see in this cap table, in the top ten we have two new major owners. Number two is Caravelle Capital. And then number ten, Marc Abitbol. These are, of course, the big changes relating to this acquisition. The Visionix acquisition will be completed during Q1 or Q2 2026. Then next, let's cover the financial guidance for 2026. And in top line, we guide currency rate-adjusted net sales to be between €190 million to €205 million, and EBITDA, excluding non-recurring items, we estimate to remain at a satisfactory level, and the assumptions behind the guidance. In the lower end, we continue to expect a more conservative performance outlook. We expect a slightly softer market environment and lower customer activity. And in the upper end, we expect improvement in the market conditions. And then, of course, successful sales execution as well.

Jouni Toijala
19:50 - 19:52

And if I may.

Jukka Kainulainen
19:52 - 19:53

Jump.

Jouni Toijala
19:53 - 20:11

Back, I think that we have had questions now regarding the guidance, and what satisfactory means. And we have been at a good level for a long time. So would you open that one a bit?

Jukka Kainulainen
20:11 - 22:41

Yes, sure. It is an excellent comment. When looking, for example, at our last year, operating adjusted EBITA for the year. So we were at 24%. And now when we look to 2026. Adjusted EBITDA. We were 17%, and now we guide that. We expect that to stay at a satisfactory level. When we communicated last year, we expected profitability to stay at a good level. That is the way to provide you with conclusions regarding our profitability guidance levels. Moving on to the next topic. Also, a reminder that one week from today, we are organizing our Capital Markets Day. So, 15th of September, where we of course will present our new strategy. We will present our combined company go-to-market plan, combined company product portfolio, our synergies, and then, of course, on top of that, our new financial targets. So welcome everyone who is able to join that event. Then at the end, as I already mentioned, we are planning this post-completion rights issue. That is a total of €80 million altogether. Nordea is our global coordinator and the underwriter for the rights issue as well. We target to arrange that during the mid to late H2 2026. And our main owners, William Demant Invest A/S, and also the sellers of the acquisition, owning altogether 31% of the shares, have irrevocably committed to subscribe the shares pro-rata based on that rights issue. And as I already commented, our target is to use the funds to repay our €80 million bridge-to-equity facility, reduce our leverage ratio, and strengthen our balance sheet altogether. Thank you.

Jouni Toijala
22:42 - 22:46

Hey. Thank you. I think it's time to move to the Q&A session, please.

Operator
22:47 - 23:04

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Nico Ruokangas from SEB. Please go ahead.

Nico Ruokangas
23:06 - 23:44

Hello, this is Nick from SEB. Thank you for the presentation. I have three questions and I would like to go one by one and start with our organic sales development, which was flat year-on-year. So if you could elaborate on that a bit more, given that it seems clearly lower than the original guidance. You had entering this year in the winter, so has something changed in the market or your own performance, or can you elaborate a bit more?

Jouni Toijala
23:45 - 26:06

I would perhaps pick that one up. So, if we look at the Q2 revenue perspective. As we have noted earlier, there may be fluctuations within certain quarters. So demand might be different. Or we have one or two slightly slower months. So if we look now and we go a bit and we break down the performance. As you mentioned, APAC was lagging behind on growth, similar to Q3 last year, Q4 last year, and Q1 this year compared to the previous comparable quarters. But the positive side is that the situation is basically improving quarter by quarter. Part of the growth we were missing from APAC; everyone knows the Middle East status. The Middle East side of the business was extremely slow regarding the regional conflict. Then if we go to Europe, Europe is in reasonably good shape, I would say. So customer activity is good. And the pipeline looks good. And in the USA, we saw slight growth and tonometers were performing well, while imaging was slightly shy, so I would not draw overly critical conclusions based on 1 or 2 months within a single quarter. Yet. So. But this is the situation now. That is the current case. So. In Q1, total revenue showed growth, and then it was reasonably stable and flat during Q2. But now, if we look at how Q3 has started. I mean, old revenue is back on the growth track. Hopefully, that answers your question.

Nico Ruokangas
26:07 - 26:14

Yes. And just to follow up, how much in rough terms was the impact from the Middle East?

Jouni Toijala
26:16 - 26:35

We do not provide country-specific numbers. Visionix also maintains business operations in the Middle East. That is visible in Visionix's one-month numbers for June.

Nico Ruokangas
26:38 - 27:29

Yeah. Understand. Thanks. Then I would like to go a bit deeper still on gross margin, which was down year-on-year in old revenue. You explained a bit more already, but I was wondering whether you can go a bit deeper into the topic, given that I guess that the gross margin was weaker than in Q4 and Q1, when price increases in the US had not been implemented well. So, completely. So, have you now been able to do all the price increases related to our stories? And then, can you be more open about the component inflation situation and what you will do about it?

Jouni Toijala
27:30 - 27:43

Maybe I can comment on the price increases. So the price increases are in; do you want to comment? I certainly commented on tariffs, but do you want to comment on components?

Jukka Kainulainen
27:43 - 28:20

Yes, of course, I can do that. Of course, the tariff impact when looking year-on-year was quite significant. We are not talking about only hundreds of thousands, as it was a more significant impact. And the unit cost impact on top of that contributed basically the rest. And as we commented, the electronic component costs are rising. And as we look further ahead, we will review what actions we can take, either by reducing the unit cost or adjusting our pricing. So those are the tools, of course, that we will use to manage the situation going forward.

Nico Ruokangas
28:24 - 29:11

Okay. Thank you. Then, one last question from me. You were reporting, I guess, €13 million of adjusted EBITA, consolidated but not pro forma, in H1. And then the pro forma was 14.6 million euros. So is it correct that Visionix generated only €1.6 million of EBITA from January to the end of May? Has it declined in H1 year on year, or is the profitability in Visionix extremely concentrated? Can you provide more detail on that?

Jukka Kainulainen
29:11 - 30:13

This is a great question. And this is, of course, I know challenging for the investors when January to May are not in the numbers, but actually the in Visionix. Of course, we know the H1 number. So there was quite a high weighting in the profitability until the end of the H1. That is the situation. And that is usually because there is some seasonality in the Visionix business. Of course, I do not comment on specific monthly Visionix numbers. January-May Visionix numbers. And then when looking at the pro forma, it is good to remember how the pro forma is calculated. It is based on the assumption that the deal was executed on January 1st, 2025. So there is also a theoretical way to build it up. That creates some slight differences when looking at where we are at the moment. But of course, it gives a good enough picture. But those I would highlight based on your question.

Nico Ruokangas
30:15 - 30:19

Okay. But if we look at the year-on-year basis, purely.

Jukka Kainulainen
30:20 - 30:34

Overall, I can comment on that. Sorry, I forgot to answer. So when looking at H1 Visionix, comparing it to last year's H1, even though we have only one month in. No significant change in the profitability profile year on year.

Nico Ruokangas
30:36 - 30:39

All right. Thank you. That is all from me at this point.

Jouni Toijala
30:39 - 30:40

Thank you.

Operator
30:43 - 30:49

The next question comes from Piero Solmi from DNB Carnegie. Please go ahead.

Piero Solmi
30:51 - 31:35

Hi, gentlemen. It's from Carnegie. I have a few questions. I will try to limit myself. If I start with the sales development now in the second quarter, I know you said you don't comment on Visionix in particular for the first half. But is there any light you can share on how Visionix fared now in the first half of this year compared to last year? Did sales for Visionix decline in the first half of this year compared to last year's first half?

Jouni Toijala
31:36 - 32:34

No. So on the top-line perspective, it was flat. If we now look at the competition and compare the performance. Even though iCare's total revenue grew during Q1. And now if we look at a flattish Q2 and then the outlook for Q3. Looking good. And then, Visionix is staying flat in the markets where we operate. I would consider it, of course, not a stellar performance, but it is quite a robust performance compared to the competition. But is there anything you would like to add on this?

Jukka Kainulainen
32:34 - 32:37

I fully agree. I think I have something to add on that.

Piero Solmi
32:39 - 33:16

Great. Thank you. Still going back to your first-quarter report, where you mentioned that price increases had been applied. I think they started to impact from February onwards. And now you reported flattish sales for the total revenue. So is it actually the case that the volumes declined in the first half and were compensated by the announced price increases?

Jouni Toijala
33:16 - 34:19

I wouldn't say so, but we have also seen the Q2 performance like you mentioned. We have also been seeing increases in component prices. Whether it is the memory, whether it is the CPU, or whether it is the increased price on gold, which is then used in the probes? So, I would not draw that conclusion. And what comes next as we look forward. We will now start to go through the detailed bill of materials. Now during the second half, we will be making decisions in the remaining part of the year on whether we should adjust prices if the memory, CPU, and raw material prices are going to remain high. So that is a standard procedure. What we do.

Piero Solmi
34:21 - 34:56

Okay. Thank you. And then in general, looking at the market sentiment and demand. And now, given your broader footprint in the market, what do you see with regards to the market demand and your sales pipeline? I know you have always underlined that the Revenio sales pipeline is short, but in Visionix, you have slightly more visibility. So, what is the current market demand?

Jouni Toijala
34:56 - 36:53

Maybe I can address that one, and you can please help me. So, USA, like we discussed in the earlier quarter. So that has been surprisingly robust. And now we have a new sales team in place. So the new combined sales team, we have split all the geographies. Et cetera. Of course, there is a certain ramp-up time, but we are looking at a strong start for Q3. It looks good. Then we have a lot of cases in the pipeline where we have not been before because we have a combined portfolio. Of course, the key is to turn them to wins. That is a crucial thing, then, if we go for Europe. Europe has been steady. And then, I hope that the APAC region turns into better shape. We have had a positive trend now, quarter by quarter. We have seen better activity, for example, in South Korea, etc. . We initiated a distributor change in Australia. That is the reason why that region has been a bit sluggish. If I may use the word earlier this year. So hopefully that is going to help the situation in APAC because that is one of the biggest regions for us in APAC. Of course, we have to remember when we report the Q3 results. So then it is going to be the first quarter where we also have Visionix numbers fully consolidated. That is going to be interesting to see.

Jukka Kainulainen
36:55 - 37:08

A positive highlight when looking at the underlying business is that the Europe region developed quite positively overall.

Piero Solmi
37:12 - 37:33

Right. Thank you. And sorry. Coming back to the gross margin and the discussion about the factors burdening that. Can you provide some guidance for your gross margin for the remainder of 2026?

Jukka Kainulainen
37:34 - 38:06

Uh, yeah. No, no. As you saw, we were guiding the EBITDA and, of course, the top line, but it is good to remember now that we only consolidated Visionix for one month. And then, of course, with the lower margin profile of Visionix, we will, when we consolidate the whole company, generate significantly more gross margin in absolute terms. But then this dilution impact will be for the whole quarter starting from quarter three. So that's that. That is a good point to remember when looking at the percentages.

Jouni Toijala
38:07 - 38:40

I do not know if that helps. Sorry to jump in. Sorry to interrupt. If we think about the third and fourth quarters. So I think on the revenue side, we have been roughly 68 to 69 depending on the quarter. And then we have the Visionix dilution part of the package. So it is further diluting. So I think that's a ballpark, right? Yes. Maybe it helps.

Unknown 1
38:40 - 38:41

All right.

Piero Solmi
38:41 - 38:46

Yeah. Thank you. I have further questions, but for now I will go back into the queue. Thank you.

Jouni Toijala
38:47 - 38:48

Okay. Thank you, Pierre.

Operator
38:51 - 38:55

The next question comes from Daniel Lepisto from Danske Bank. Please go ahead.

Daniel Lepisto
38:57 - 39:26

Hi, it is Daniel from Danske Bank. Thanks for taking my questions. I have a couple of questions, perhaps starting with or continuing on the organic growth of revenue. I mean, if you didn't execute this Visionix transaction, would the previous guidance of 8% to 15% growth this year still be in place after Q2? That is the first question.

Jouni Toijala
39:26 - 39:51

I think that I am not too sure if it is a relevant question at this new state, but I would not see it that way. So we have also the big deals in a pipeline for the remaining part of the year. And Q3 or Q4 is basically strong. So, the forecast looks good.

Daniel Lepisto
39:53 - 40:03

Okay. A follow-up would be regarding those larger deals that you discussed. So they are still on the table. I expect a stronger second half.

Jouni Toijala
40:03 - 40:21

Yeah. So, yes. For certain cases, we have been receiving single-product requests. So, it is still alive and kicking. Of course, the timing and rollout are always a question mark.

Daniel Lepisto
40:23 - 40:54

Okay. That's clear. Then on this margin guidance, the satisfactory margin, I mean, how wide should we think the range is here since I guess historically, you know, with the EBIT margin, I guess it used to be even 10 percentage points. It felt like it. But basically, how wide can this range be; can you go into single digits on it? EBITDA. And it would still be considered satisfactory.

Jukka Kainulainen
40:54 - 41:23

You were not far off what you commented in the beginning, but maybe I am repeating myself. So last year, our adjusted EBITA was 24%. And now when you look at just the EBITA in the second quarter, we were in. 17%. I apologize that I cannot comment further on that because that is what we have disclosed, but I hope that helps you understand what kind of range we have in place for that wording.

Daniel Lepisto
41:26 - 41:51

Okay. Then, maybe on the standalone revenue gross margin, there was a five percentage point decrease year-on-year, so it is clearly below 70%. The comparison was of course difficult. But I guess in the mid-term, 70% is still the target you are looking for in revenue, or has this changed? I think it changed due to the component shortages and related factors.

Jouni Toijala
41:53 - 42:44

Maybe I will pick that one. Daniel. So, I think it is realistic to think that, yes, we have had the target before the tariffs took effect to keep it above the 70%, which we have been able to do. And now that the tariffs are fully in effect, we have been in the ballpark of, depending on the quarter, 68%, 69%, and so forth. I think that it would be reasonable to expect. And of course, we don't have to report the old revenue anymore in Q2, as we did in Q1. If we use that term. But if we go for the old revenue, I think it's fair to assume that it will be constantly over 70. So that is doable with the tariffs.

Daniel Lepisto
42:47 - 43:13

Okay. That's that's clear. This may be the final question on this. Ellen, regarding the AI solution clinical trials. Obviously, we saw that now the third-party solution was approved. Can you update us on the timeline with your own solution? What is the status of the clinical trials and what is the approval timeline that you seek?

Jouni Toijala
43:14 - 44:36

We have now concluded the pre-study. Results are good. The results are satisfactory. Now we are doing a new pre-submission just to be sure. And of course, now the iHealthScreen deal has reduced the pressure to push aggressively forward; rather, we are now in a mode where we guarantee that we get the clearance when we do it. So the status is that the pre-study is done and now we filed another pre-submission for the FDA to be sure that the house is in order. Then we start another study. Then, towards the end of the year or early next year. We previously communicated that we expect to be ready for clearance by the end of the first half. 2027. I would now be more leaning towards the second half. Hopefully, Q3 2027. And the reason is that now we have the iHealthScreen clearance, so we just want to be sure that we are able to get the clearance. So we are doing the pre-submission to the FDA again.

Daniel Lepisto
44:39 - 44:42

All right. That is clear. So from me. Thank you.

Operator
44:46 - 44:50

The next question comes from Eric Carlson. Please go ahead.

Erik Karlsson
44:53 - 45:23

Hi, thanks for taking my questions. Erik Karlsson from Google, just on Visionix. If we look at the first-half performance, you mentioned basically flat sales and flat margins. How much worse is that compared to your business case? You bought it; I guess at the time you thought they would grow and have increasing margins even before synergies. I am just trying to understand how far below expectations they are currently tracking.

Jouni Toijala
45:24 - 45:34

And that is according to the expectations. What we baked into the model was based on the timing of the closing.

Erik Karlsson
45:35 - 45:37

Did you expect them to grow, or did you think they would improve margins?

Jouni Toijala
45:38 - 46:20

No, if we look at the timing and the process, of course, we had the forecast for the first half and for the second half. And then we started to pack into the numbers by the closing so that we are able to start getting the synergies in terms of the OpEx savings and the commercial synergies. So, basically, Visionix is performing according to our expectations at the time of signing and closing the deal. Visionix has been performing in line with our expectations during the first half. What was our expectation at the time of the signing and closing of the deal?

Erik Karlsson
46:23 - 46:34

Okay. It sounded like when you did the acquisition, they had an internal plan to improve gross margins, because I think I was quite shocked by the low profitability they had at the time.

Jouni Toijala
46:36 - 47:44

I think if we compare the profitability of Revenio and Visionix to the industry in general. So, the Visionix numbers have been in the black, while almost everyone else has been in the red. That was basically known. And then regarding Visionix. So we have had this internal efficiency plan, which they put in place at the time of the negotiations and a bit before that. So that's progressing. And as I said earlier, we have been able to secure 5 million out of the 20 million in synergies so far. So that work is constantly moving forward. The plan is to improve the EBITDA level and increase margins to 25% by the end of 2029. So the plan is in place and it is progressing according to the plan.

Erik Karlsson
47:46 - 48:25

Okay. Got it. And then on the profit guidance, I don't know who advised you on this, but I think there are two ways to go. One is that you do not want to tell the market and therefore do not guide, or you want to help the market and you do guide. And what the market wants is numbers. They don't want soft guidance. It just becomes like a game to translate that into numbers. So I think either way it is fine to go. But to start saying what that strategy is for you might not be for me. So we just get into this ridiculous game. So I think, if I were you, I would either not guide on it or I would just put a number out there or a range. Does that make sense to you?

Unknown 2
48:25 - 48:26

Sense to you?

Jukka Kainulainen
48:27 - 48:34

Great feedback. Thanks. Thanks a lot. We appreciate that a lot. So yeah, we will, of course.

Jouni Toijala
48:34 - 49:43

Yeah, yeah. I agree that has been the history that, as you said, we have objectives to describe the growth and describe the profitability. Now, what we have been trying to improve is that we gave a bracket for the top line and still made the decision to use an objective for the bottom line part. So that is going to remain for sure for the remaining part of the year. But I think this is constantly asked of us: should we actually give a euro amount or should we give a percentage amount? So we will take that input into account and see then in February how we go forward. Sure. But thank you, Eric, for the very good feedback. And we have heard that feedback earlier that it is not fully clear.

Erik Karlsson
49:44 - 49:45

Super. Thank you so much.

Jouni Toijala
49:46 - 49:48

Thank you for the good questions.

Operator
49:50 - 49:55

The next question comes from Pierre Salameh from Carnegie. Please go ahead.

Piero Solmi
49:58 - 50:31

Hi, gentlemen. Thank you. Still a few questions, if I may. And now I am going back to the synergy potential you have described. You have presented. So you target an adjusted EBITDA uplift of €20 million by the end of 2029. I am just trying to ask for clarification here. Regarding this €20 million uplift, is operational leverage included or excluded from this figure?

Jouni Toijala
50:33 - 50:43

So are you able to elaborate a bit on what you mean by the operational uplift?

Piero Solmi
50:44 - 51:01

Operational leverage, I mean, assuming your sales will grow. There is some operational leverage in your system. So, I am just checking if I understood your ambition to raise the adjusted EBITDA level by 20 million.

Unknown 1
51:03 - 51:03

Okay.

Piero Solmi
51:03 - 51:09

In this discussion, how about growth and the implications from that?

Jouni Toijala
51:09 - 53:02

Okay. Okay. Hey, hey. Thank you. You can correct me if I am wrong, but at the time when we announced the transaction and at the time of the closing, we iterated the €20 million EBITDA uplift. And the big part of that comes from the OpEx-related synergies, right? Now, if we consider the first €5 million. So what we now have been able to achieve. That is coming from the operational side, specifically from the integration of the Visionix US team and the Revenio US team. And that is coming from the OpEx side. Then we also have a commercial component. The cross-sell and upsell part, which is also part of the €20 million EBITDA uplift, comes more from the operational side. And we haven't split the ratio. But if you would look at the picture, what we use is the waterfall where there's a first commercial part and then there's an OpEx part. So you get a sense and feel for how it is divided, and then the scaling of the OpEx and that part. If we grow, you get the scale from that growth, but there is only this cross-sell and upsell part that we count as a synergy. So not in a way the normal organic. Do you have anything to add on this?

Jukka Kainulainen
53:02 - 53:15

Of course, when you grow, you always lead the business in a way that top-line growth is quicker than the fixed costs. So if you refer to that. That is a separate topic, of course.

Piero Solmi
53:17 - 53:35

Yes, exactly. That was my point. So, 20 million is the synergy target, and anything you might grow upon in addition to that brings more leverage to the equation.

Jouni Toijala
53:36 - 53:37

Yes. Fully agree.

Unknown 1
53:39 - 53:39

Yes.

Piero Solmi
53:39 - 54:18

Uh, All right. Thank you. Then just shortly, when I skimmed through the report, did you directly comment on sales impacts from Visionix selling your products? So, kind of internal sales that will be eliminated, or even broadening the question to potential overlapping products. Have you taken this into account in the pro forma numbers?

Jukka Kainulainen
54:18 - 54:25

Yes, it has been taken into account. I think it was approximately 300,000 when looking at the 2025 numbers. So that has been taken into account.

Unknown 1
54:26 - 54:27

All right.

Piero Solmi
54:28 - 54:49

Uh okay. Thank you. And then finally, if I can still get the clarification, what is the net working capital to sales profile for the combined company? In what ballpark do you see the combination? Say. Yea yea.

Unknown 1
54:49 - 54:49

Yea.

Jukka Kainulainen
54:50 - 55:07

Yea. Overall, these are rough numbers. When looking at working capital for the combined company at the end of the second quarter, it was at the 60 million level. And of course, we will constantly continue optimizing that going further.

Piero Solmi
55:11 - 55:15

Uh all right. I think this is all for now. Thank you.

Jouni Toijala
55:17 - 55:18

Thank you.

Jukka Kainulainen
55:18 - 55:19

Thank you.

Operator
55:20 - 55:24

The next question comes from Nico Ruokangas from Seb. Please go ahead.

Nico Ruokangas
55:26 - 56:04

Hello, this is Nicolas again. I have a couple of clarifying questions. Still, and maybe now on EBITDA, as you are now starting to report that as a headline KPI. So, out of these today, since you are expecting to report in H2 or on a run-rate basis going forward. So how is that divided between the amortization of old revenue standalone amortization and the PPA from this transaction?

Jukka Kainulainen
56:05 - 56:33

Yeah. So this amortization includes, of course, all of those. When looking a little bit at the details, the Visionix acquisition brings around 6 million in new PPA depreciation. And then on top of that other amortization, we have around 2 million, a little bit more than 2 million. So we are at around an 8 million level, even higher than an 8 million annualized number going forward.

Nico Ruokangas
56:37 - 56:58

Thank you. Then you were discussing the. Post-rights issue of roughly 2.5 times in time of the announcement of the acquisition. Is this still relevant? Is that still the target? Uh, around reach.

Jukka Kainulainen
56:58 - 57:32

Of course, of course. At some point, yes. I think when looking at the current net debt to EBITDA, which was 5.3 in quarter two and after the share issue, it goes closer to three when looking at the current estimates. But of course, we continue generating cash and profit going forward. So that will improve the leverage ratio quarter over quarter. But that's the short-term view.

Nico Ruokangas
57:33 - 58:01

Yeah. Thank you. And then, still on strategy, which we have been already discussing. But then, I guess that the basis for the tariffs has to be changed now, over this one-year period. Do you think that you could receive tariff refunds for the tariffs you have paid under the old basis of tariffs?

Jukka Kainulainen
58:03 - 58:14

Yeah. This is something we are looking after regarding the refunds from the tariffs. So this is what we are working on at the moment.

Nico Ruokangas
58:16 - 58:19

All right. Thank you. That is all from me.

Jouni Toijala
58:20 - 58:21

Thank you.

Jukka Kainulainen
58:21 - 58:22

Thank you.

Operator
58:24 - 58:29

There are no more questions at this time. So I hand the conference back to the speakers.

Jouni Toijala
58:31 - 59:41

Hey, thank you all. Extremely active call. And if I may summarize at the end. So integration is moving extremely well forward. So I would not be too concerned about that. We have managed to realize 5 million out of the 20 million discussed EBITDA uplift already, with sales teams integrated and the USA operative model moving swiftly forward. Then also, on the channel side in the rest of the world, we have moved to execution. Then we are going to have exciting news coming on the OCT segment. So we continue working extremely hard here in order to grow the top line, finalize the integration, and get the margins up. Thank you for your participation, and we are really looking forward to catching up. Then during the Q3 earnings call, thank you for your time and interest.

Jukka Kainulainen
59:41 - 59:41

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…